全文获取类型
收费全文 | 4696篇 |
免费 | 351篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 39篇 |
儿科学 | 77篇 |
妇产科学 | 124篇 |
基础医学 | 591篇 |
口腔科学 | 32篇 |
临床医学 | 611篇 |
内科学 | 904篇 |
皮肤病学 | 41篇 |
神经病学 | 480篇 |
特种医学 | 166篇 |
外科学 | 668篇 |
综合类 | 120篇 |
一般理论 | 7篇 |
预防医学 | 401篇 |
眼科学 | 109篇 |
药学 | 383篇 |
中国医学 | 9篇 |
肿瘤学 | 295篇 |
出版年
2023年 | 20篇 |
2022年 | 36篇 |
2021年 | 62篇 |
2020年 | 50篇 |
2019年 | 78篇 |
2018年 | 107篇 |
2017年 | 74篇 |
2016年 | 103篇 |
2015年 | 121篇 |
2014年 | 147篇 |
2013年 | 207篇 |
2012年 | 340篇 |
2011年 | 358篇 |
2010年 | 198篇 |
2009年 | 166篇 |
2008年 | 295篇 |
2007年 | 340篇 |
2006年 | 316篇 |
2005年 | 325篇 |
2004年 | 323篇 |
2003年 | 269篇 |
2002年 | 243篇 |
2001年 | 60篇 |
2000年 | 60篇 |
1999年 | 60篇 |
1998年 | 55篇 |
1997年 | 47篇 |
1996年 | 39篇 |
1995年 | 38篇 |
1994年 | 33篇 |
1993年 | 37篇 |
1992年 | 35篇 |
1991年 | 34篇 |
1990年 | 30篇 |
1989年 | 31篇 |
1988年 | 27篇 |
1987年 | 29篇 |
1986年 | 21篇 |
1985年 | 28篇 |
1984年 | 22篇 |
1983年 | 15篇 |
1982年 | 19篇 |
1981年 | 12篇 |
1980年 | 14篇 |
1979年 | 20篇 |
1977年 | 13篇 |
1976年 | 10篇 |
1975年 | 9篇 |
1974年 | 12篇 |
1973年 | 8篇 |
排序方式: 共有5057条查询结果,搜索用时 937 毫秒
131.
132.
M. Alexander J. King A. Bajel C. Doecke P. Fox S. Lingaratnam J. D. Mellor L. Nicholson I. Roos T. Saunders J. Wilkes R. Zielinski J. Byrne K. MacMillan A. Mollo S. Kirsa M. Green 《Internal medicine journal》2014,44(10):1018-1026
These consensus guidelines provide recommendations for the safe handling of monoclonal antibodies. Definitive recommendations are given for the minimum safe handling requirements to protect healthcare personnel. The seven recommendations cover: (i) appropriate determinants for evaluating occupational exposure risk; (ii) occupational risk level compared with other hazardous and non‐hazardous drugs; (iii) stratification of risk based on healthcare personnel factors; (iv) waste products; (v) interventions and safeguards; (vi) operational and clinical factors and (vii) handling recommendations. The seventh recommendation includes a risk assessment model and flow chart for institutions to consider and evaluate clinical and operational factors unique to individual healthcare services. These guidelines specifically evaluated monoclonal antibodies used in the Australian cancer clinical practice setting; however, the principles may be applicable to monoclonal antibodies used in non‐cancer settings. The guidelines are only applicable to parenterally administered agents. 相似文献
133.
134.
Richard B Pollard Jürgen K Rockstroh Giuseppe Pantaleo David M Asmuth Barry Peters Adriano Lazzarin Felipe Garcia Kim Ellefsen Daniel Podzamczer Jan van Lunzen Keikawus Arastéh Dirk Schürmann Bonaventura Clotet W David Hardy Ronald Mitsuyasu Graeme Moyle Andreas Plettenberg Martin Fisher Birger Sørensen 《The Lancet infectious diseases》2014,14(4):291-300
135.
136.
137.
138.
139.
Arinaminpathy N Ratmann O Koelle K Epstein SL Price GE Viboud C Miller MA Grenfell BT 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(8):3173-3177
Large-scale immunization has profoundly impacted control of many infectious diseases such as measles and smallpox because of the ability of vaccination campaigns to maintain long-term herd immunity and, hence, indirect protection of the unvaccinated. In the case of human influenza, such potential benefits of mass vaccination have so far proved elusive. The central difficulty is a considerable viral capacity for immune escape; new pandemic variants, as well as viral escape mutants in seasonal influenza, compromise the buildup of herd immunity from natural infection or deployment of current vaccines. Consequently, most current influenza vaccination programs focus mainly on protection of specific risk groups, rather than mass prophylactic protection. Here, we use epidemiological models to show that emerging vaccine technologies, aimed at broad-spectrum protection, could qualitatively alter this picture. We demonstrate that sustained immunization with such vaccines could--through potentially lowering transmission rates and improving herd immunity--significantly moderate both influenza pandemic and seasonal epidemics. More subtly, phylodynamic models indicate that widespread cross-protective immunization could slow the antigenic evolution of seasonal influenza; these effects have profound implications for a transition to mass vaccination strategies against human influenza, and for the management of antigenically variable viruses in general. 相似文献
140.